Stem-cell biotech company PrimeGen US has signed a major merger agreement with DT Cloud Star Acquisition Corp, in a deal valued at approximately $1.49–$1.5 billion. The transaction is expected to close in the second half of 2026, subject to shareholder and regulatory approvals.
Once completed, PrimeGen US will become a publicly listed company on Nasdaq. The deal is structured as a stock-for-stock transaction, meaning payment will be made in shares rather than cash.
About PrimeGen US
PrimeGen US is a leading biotech firm specializing in stem-cell and exosome-based medical research. Its primary focus is on developing innovative therapies for acute liver injury and related diseases.
The company recently completed a Pre-IND (pre-Investigational New Drug) meeting with the FDA, paving the way for its main therapy programs to advance into clinical trials.
About DT Cloud Star
DT Cloud Star is a Special Purpose Acquisition Company (SPAC). SPACs are designed to acquire private companies and bring them to public markets efficiently.
Through this merger, PrimeGen US will gain direct access to Nasdaq, providing the company with capital to fund research and expand its clinical programs.
Key Highlights of the Deal
| Aspect | Details |
| Deal Type | SPAC Merger |
| Companies | PrimeGen US + DT Cloud Star Acquisition Corp |
| Valuation | $1.49 – $1.5 Billion |
| Payment | Stock-based |
| Objective | Nasdaq listing, capital for stem-cell research and clinical trials |
Why the Merger Matters
Experts say this deal could be a significant milestone for stem-cell therapeutics. By merging with a SPAC, PrimeGen US can go public faster than via a traditional IPO route.
The company will gain access to new investors, strengthen its financial position, and accelerate its research programs. However, the success of the merger is contingent on FDA approvals and shareholder consent.
Implications for Investors
Market analysts note that SPAC mergers often involve initial volatility in stock prices. Given the growing demand in stem-cell and biotech sectors, investors will likely watch this merger closely.
Outcome
The PrimeGen US and DT Cloud Star merger represents a new chapter for biotech SPAC deals. With a valuation of $1.5 billion, the transaction will provide PrimeGen US with significant capital and a Nasdaq listing, enabling it to advance stem-cell therapy development more rapidly.
Source: prnewswire
